Allergen Immunotherapy for Allergic Rhinitis Has Favorable Real-World Outcomes

Clinicians can use tips from the ACAAI to help patients manage their allergy symptoms.
Clinicians can use tips from the ACAAI to help patients manage their allergy symptoms.
A prospective, single-center study examined the use of allergen immunotherapy for alleviating the burden of allergic rhinitis.

The following article is a part of conference coverage from the American College of Allergy, Asthma & Immunology 2021 Annual Scientific Meeting, being held virtually from November 4 to 8, 2021. The team at Pulmonology Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the ACAAI 2021 Annual Scientific Meeting.


In real-world clinical practice, allergen immunotherapy significantly reduced symptomatic medication intake and increased quality of life and patient satisfaction in patients with allergic rhinitis, according to research findings presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, held in New Orleans, LA, November 4 to 8, 2021.

The prospective cohort study was an analysis of clinical data of 115 patients with allergic rhinitis (mean age, 27.9 years; 55.7% male) who received subcutaneous allergen immunotherapy in South Portugal. Some patients also had asthma (31.3%) and atopic dermatitis (13.9%). Patients received allergen immunotherapy, with 79.1% of all formulations containing Dermatophagoides pteronyssinus extract.

Researchers examined each patient’s combined symptom and medication score (CSMS), which was recorded before each monthly administration of allergen immunotherapy. Additionally, the investigators examined responses to a mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQlQ), which was administered at baseline as well as after each year of treatment. A treatment-specific questionnaire was also assessed to determine levels of patient satisfaction with treatment.

In an analysis adjusted for sex, age, and concomitant allergic disease, there was a significant reduction in CSMS from baseline after 12 administrations of allergen immunotherapy (P <.0001). Reduction in CSMS was greater between the sixth and eighteenth administration of therapy. After 12, 24, and 36 months, 24%, 62%, and 89% of patients, respectively, were medication-free. Both miniRQLQ and ESPIA scores significantly improved with each year of allergen immunotherapy (P <.0001 for both).


Silva P. Allergen immunotherapy: Clinical outcomes data from a real-world clinical practice. Presented at: American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting; November 4-8, 2021; New Orleans, LA. P027.